Abstract
BackgroundThe development of new bispecific antibodies such as bispecific T cell engagers (BiTE) is a hot avenue in cancer immunotherapy. BiTE antibodies interact simultaneously with epitopes located on T cells...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
